200% Tariff: Trump Hits Pharmaceutical Industry

According to Forbes, Donald Trump announced at a Cabinet meeting that he would announce a decision on tariffs on pharmaceutical products "very soon. " The proposal would give companies "about a year" to relocate production to the US before tariffs, which would reach as high as 200 percent, are imposed.

Experts suggest that imposing tariffs on pharmaceutical products could lead to higher prices for Americans. Forbes cited John Murphy III, CEO of the Association for Accessible Medicines, as saying in April of this year that "tariffs will only exacerbate the problems that already exist in the U.S. affordable medicines market."

Eli Lilly CEO David Ricks, in turn, suggested that the tariffs could force the company to reduce its investment in research and development , Forbes reports.

According to experts , generic drugs are most at risk because they have a much lower profit margin than branded drugs, which can more easily absorb the additional costs resulting from tariffs.

At the same time, Forbes reports that opioids and ADHD medications are the least likely to be affected by tariffs - they are largely produced in the US due to additional restrictions.

In 2024, the largest drug suppliers to the US were:

• Ireland ($50.3 billion),
• Switzerland ($19 billion),
• Germany ($17.1 billion),
• Singapore ($15.3 billion),
• India ($12.5 billion).

Copyrighted material - reprint rules are specified in the regulations .